Reverse cholesterol transport and atherosclerosis regression.
Spady
D K
DK
D000818:Animals; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000008:administration & dosage / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001692:Biological Transport; D002352:Carrier Proteins / Q000378:metabolism; D002784:Cholesterol / Q000737:chemistry / Q000378:metabolism*; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters / Q000378:metabolism; D006023:Glycoproteins; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D008081:Liposomes / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism*; D051379:Mice; D010743:Phospholipids / Q000008:administration & dosage / Q000627:therapeutic use; D011498:Protein Precursors / Q000008:administration & dosage / Q000627:therapeutic use
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters; D006023:Glycoproteins; D008074:Lipoproteins; D008081:Liposomes; D010743:Phospholipids; D011498:Protein Precursors; D002784:Cholesterol